Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. reports developments as a clinical-stage biotechnology company focused on mast cell biology and antibody-based therapeutics for allergic, inflammatory, autoimmune and other mast cell-mediated diseases. Company updates center on barzolvolimab, a humanized monoclonal antibody being studied across chronic spontaneous urticaria, cold urticaria and symptomatic dermographism, as well as pipeline work that includes CDX-622 in asthma.
Recurring news themes include clinical data presentations at allergy and dermatology meetings, financial results, corporate updates and capital actions. Celldex also reports financing activity tied to its common stock and development priorities for its antibody-based immunology pipeline.
Celldex (NASDAQ:CLDX) reported second quarter 2026 results and a pipeline update. Cash, cash equivalents and marketable securities were $717.6 million at June 30, 2026, boosted by $323.8 million in net proceeds from an April underwritten public offering, with cash expected to fund operations through 2028. Q2 R&D expenses were $67.5 million and G&A expenses $13.1 million, leading to a net loss of $73.5 million, or ($0.94) per share.
The Phase 3 barzolvolimab chronic spontaneous urticaria program (EMBARQ-CSU1/2) fully enrolled 1,939 patients six months ahead of guidance, with topline data expected Sept/Oct 2026 and a planned 2027 BLA. A Phase 3 barzolvolimab study in cold urticaria and symptomatic dermographism is ongoing, and Phase 2 atopic dermatitis data are expected in late 2026. The Phase 2 prurigo nodularis study did not meet endpoints and is being discontinued. First-in-human Phase 1 data for bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and good tolerability, supporting expansion into additional inflammatory indications.
Celldex (NASDAQ:CLDX) reported topline Phase 2 results for subcutaneous barzolvolimab in prurigo nodularis (PN). The 140‑patient, randomized, placebo‑controlled study did not meet its primary endpoint of ≥4‑point WI‑NRS itch reduction at Week 12 or key secondary endpoints, at either 150mg or 300mg Q4W after a 450mg loading dose.
According to Celldex, barzolvolimab produced rapid, profound and sustained systemic mast cell depletion, shown by significant serum tryptase reductions, but this did not improve itch or skin lesions versus placebo, suggesting mast cells may not be a key PN driver. Based on these data, the company is discontinuing the PN Phase 2 study. Safety and tolerability were favorable and consistent with prior trials, including with the new 450mg loading regimen. Barzolvolimab continues in Phase 3 studies for chronic spontaneous urticaria, symptomatic dermographism and cold urticaria, and in a Phase 2 study in atopic dermatitis, with CSU Phase 3 topline data expected in September/October 2026.
Celldex (NASDAQ:CLDX) announced that Senior Vice President and Chief Financial Officer Sam Martin plans to retire in 2027. Martin, CFO since 2017 and with Celldex since 2009, will remain in his role through March 2027 while the company conducts a CFO search.
According to Celldex, Martin has helped guide its evolution toward a late-stage immunology company. The company highlights a robust pipeline and notes that key data from two Phase 3 barzolvolimab trials are expected later in 2026.
Celldex (NASDAQ:CLDX) reported long-term Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU) with angioedema. Treatment produced rapid, significant and durable angioedema improvements that persisted seven months after final dosing.
Up to 64% of baseline angioedema patients were angioedema-free at Week 76. Two Phase 3 CSU trials (1,939 patients) are fully enrolled, with topline data expected in Q4 2026 and a planned BLA filing in 2027.
Celldex (NASDAQ:CLDX) reported first-in-human Phase 1 results for CDX-622, a bispecific antibody targeting soluble SCF and TSLP, at the EAACI 2026 meeting.
According to Celldex, CDX-622 produced rapid, profound, dose-dependent, durable serum tryptase reductions, showed monoclonal-like pharmacokinetics, and was well-tolerated without dose-limiting toxicities, serious related events, or immunogenicity. Non-human primate data supported selective mast cell depletion without measurable effects on spermatogenesis or melanogenesis.
Celldex (NASDAQ:CLDX) will present new data from its mast cell–targeting pipeline at the 2026 European Academy of Allergy and Clinical Immunology Congress in Istanbul, Türkiye, on June 12-15, 2026.
Three presentations cover barzolvolimab in chronic spontaneous and cold urticaria and first-in-human Phase 1 data for bispecific antibody CDX-622 in healthy volunteers.
Celldex (NASDAQ:CLDX) reported Q1 2026 results and an operational update on May 7, 2026. Key points: Phase 3 CSU enrollment finished six months early (1,939 patients), topline CSU data expected Q4 2026, BLA planned for 2027, multiple 2026 readouts expected, and a $345M follow-on financing closed in April 2026.
Cash as of March 31, 2026: $451.5M; net loss Q1 2026: $78.7M (−$1.18/share).
Celldex (NASDAQ:CLDX) management will appear in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 3:30 pm ET. The live webcast will be available in the Investors > Events & Presentations section and replays will remain for 90 days.
Celldex Therapeutics (Nasdaq: CLDX) closed an underwritten public offering of 11,896,750 common shares on April 6, 2026, including full exercise of the underwriters’ option for 1,551,750 additional shares.
The public offering price was $29.00 per share, and gross proceeds to Celldex were approximately $345 million, before underwriting discounts, commissions and offering expenses.
Celldex (Nasdaq: CLDX) priced an underwritten public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million in gross proceeds before underwriting discounts. The underwriters have a 30-day option for an additional 1,551,750 shares. Closing is expected on or about April 6, 2026. Celldex said net proceeds will fund commercial readiness and a potential U.S. launch of barzolvolimab (if approved), ongoing clinical and preclinical development, expansion of its bispecific antibody platform, pipeline development, and general corporate purposes.